A Bioelectronic Medicine Company

advancing the treatment of autoimmune disease symptoms.

About Us

Boomerang Medical is on a mission to disrupt the treatment of bowel urgency symptoms in patients with ulcerative colitis (UC). The company is developing a bioelectric neuromodulation technology, which has been granted Breakthrough Device Designation by the FDA, currently being evaluated in an FDA-approved clinical trial studying ulcerative colitis at leading Inflammatory Bowel Disease (IBD) centers in the US.

Our Focus

IBD is one of the most debilitating autoimmune diseases, affecting millions globally. Living with IBD impacts not just physical health, but also work, relationships, and well-being. Current treatments include medications and surgery, but the complexity of the condition means that there is always room for innovative approaches.

What if the next big leap in managing IBD symptoms is already hardwired into our bodies? That's the question propelling our focus on neuromodulation, a promising frontier in bioelectronic medicine.

Boomerang Medical is dedicated to promoting IBD awareness and education. We are proud to be a member of the Crohn’s & Colitis Foundation's Corporate Circle.

Boomerang Medical is headquartered in the heart of Silicon Valley on the campus of El Camino Hospital in Mountain View, California. We are proud to be a Company–In-Residence at the prestigious Fogarty Innovation incubator–the only healthcare-focused incubator of its kind in the US–giving us access to the brightest minds and expertise in the medical technology industry.

Does Ulcerative Colitis disrupt your daily life?

Researchers in the BOOM-IBD2 Clinical Trial are exploring whether neuromodulation, a therapy already approved by the FDA to treat other conditions, can be effective in the treatment of bowel urgency symptoms in patients with ulcerative colitis.

Click here to learn more

Meet the Team

Shehab

Chief Executive Officer

Tom Shehab, MD

Tom practiced medicine for 15 years as a gastroenterologist and he brings his experience as a physician, healthcare executive, and investor focused on medical device and health IT companies to Boomerang Medical. He serves on the boards of Endogenex, Motif Neurotech, and Virtual Incision, and previously led Arboretum’s investment in nVision Medical.

Co-Founder, Chief Technology Officer

David Miller, MEng

David is an innovator and entrepreneur, holding more than 50 patents spanning diverse technologies and clinical applications. With over 20 years of experience, David has co-founded multiple companies, is a Stanford BioDesign Fellow, and was previously a Distinguished Scientist and Technical Fellow at Medtronic.

Vice President, Therapy Development

Lucas Payne

Lucas has 20+ years of experience leveraging his passion for patient care, HCP training and entrepreneurship to advance Class III medical device innovation for companies such as Johnson & Johnson and Abbott. Lucas began his career in the medical field in patient care as a radiation technologist.

Vice President, Clinical & Regulatory

Bruce Van Deman

Bruce is a clinical research and medical sciences executive with extensive experience leading clinical trials, regulatory strategy, evidence generation and physician engagement across medical technology companies. He has held senior leadership roles at Medtronic, Edwards Lifesciences, NeoChord and Conformal Medical, supporting pivotal studies, product development, reimbursement and commercialization.

Senior Director, Clinical Strategy and Safety

Colleen Holthe

Colleen has a deep understanding of clinical research and regulatory affairs within the medical device industry. She holds 20+ years of experience conducting 25 clinical trials and a proven track record of leading Class III medical device trials from inception to FDA approval.

Senior Director, Clinical Therapy Development

Malea D'Amico, CCRA, CCRP

Malea has spent 21 years on the front lines of clinical research in over 70 medtech and biotech clinical trials. An expert in clinical study quality assurance, her experience crosses all phases clinical trials including benchwork, QA, monitoring, field support and patient outreach.

Board of Directors + Advisors

Boomerang Medical is proud to be a portfolio company of

Arboretum Ventures and Hatteras Venture Partners, as well as a

Company-In-Residence at Fogarty Innovation.

Tom Shehab, MD

Arboretum Ventures

Managing Partner

Andrew Cleeland

Fogarty Innovation

Chief Executive Officer

Jeff Terrell

Arboretum Ventures

General Partner

Gayle Kuokka

Fogarty Innovation

Chief Financial Officer

Lauren Flickinger

Hatteras Venture Partners

General Partner

Screen Shot 2022-10-10 at 11_edited_edit

John Morriss

Fogarty Innovation

Director of Innovation Acceleration

Scientific Advisors

Peter Irving, MA, MD, FRCP

Co-PI of BOOM-IBD2 Pivotal Trial

Guy’s and St Thomas’ NHS Foundation Trust

Consultant Gastroenterologist

Kings College London

Professor of Inflammatory Bowel Disease

Edward Barnes, MD, MPH

Co-PI of BOOM-IBD2 Pivotal Trial

University of North Carolina at Chapel Hill

Associate Professor of Medicine,

Co-Director of Multidisciplinary IBD Center

Corey A. Siegel, MD, MS

Laura Raffals, MD

Warren Grill, PhD

Chief Scientific Advisor

Scientific Advisory Board Member

Scientific Advisor

Dartmouth-Hitchcock Medical Center

Section Chief of Gastroenterology and Hepatology, Co-Director of the IBD Center

Duke University

James B. Duke Distinguished Professor of Biomedical Engineering at Duke University

Mayo Clinic

Professor of Medicine, Department of Medicine Associate Chair of Faculty Development, Vice Chair of the Division of Gastroenterology & Hepatology

Boomerang Medical in the News

Anchor 1

Good Girl Greta: What the Body Was Saying All Along

Columbia Surgery I May 13, 2026

On a recent afternoon, not long after she crossed into her second trimester, filmmaker Rachel Ross found herself doing something she hadn’t been able to do in years: walking through New York without planning every exit.

Boomerang Medical raises $20M Series B for IBD Pivotal Trial, with Arboretum and Hatteras Returning as Lead Investors

Business Wire | Sept 4, 2025

Trial evaluates neuromodulation for ulcerative colitis, the most common form of IBD.

How a New Clinical Trial for IBD Is Changing Frank's Life

Columbia Surgery I October 13, 2024

Frank Soldano's life has been a rollercoaster of medical challenges, resilience, and hope. For over two decades, he has battled the debilitating effects of inflammatory bowel disease...

2495 Hospital Drive, Suite 300

Mountain View, CA 94040

(650) 564-3076

info@boomerangmedical.com